

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number
WO 03/106402 A1

(51) International Patent Classification⁷: C07C 235/34, C07D 209/20, 213/55, 333/24, A61K 31/197, 31/405, A61P 13/00

(21) International Application Number: PCT/EP03/05705

(22) International Filing Date: 30 May 2003 (30.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0213488.0 12 June 2002 (12.06.2002) GB

(71) Applicant (for all designated States except US): BAYER AKTIENGESELLSCHAFT [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SHIMAZAKI, Makoto [JP/JP]; 5-5-3-1, Kunimidai, Kizu-cho, Soraku-gun, Kyoto 619-0216 (JP). SAKURAI, Osamu [JP/JP]; 11-15, Koaza-Hiroshiki, Aza-Oyamazaki, Oyamazaki-cho, Otokuni-gun, Kyoto 618-0071 (JP). MURATA, Toshiki [JP/JP]; 1-3-501, Nakano-cho, Ikoma-shi, Nara 630-0267 (JP). URBAHNS, Klaus [DE/JP]; 6-3-1-301, Kusugaoka-cho, Nada-ku, Kobe, Hyogo 657-0024 (JP). YAMAMOTO, Noriyuki [JP/JP]; 6-6-1-3-404, Jingu, Nara-shi, Nara 631-0804 (JP). YOSHIKAWA, Satoru [JP/JP]; 4-10-6, Shibatsuji-cho, Nara-shi, Nara 630-8114 (JP). UMEDA, Masaomi [JP/JP]; 2-840-156, Sahodai, Nara-shi, Nara 630-8105 (JP). TAJIMI, Masaomi [JP/JP]; 1-8-17, Sakuragaoka, Seika-cho, Soraku-gun, Kyoto 619-0232 (JP). MASUDA, Tsutomu [JP/JP]; 3-15-6-6A, Jingu, Nara-shi, Nara 631-0804 (JP). SHINTANI, Takuya [JP/JP]; 4-24-1, Seikadai, Seika-cho, Soraku-gun, Kyoto 619-0238 (JP). SHIMIZU, Haruka [JP/JP]; 88, B-202, Aono-cho, Nara-shi, Nara 631-0841 (JP).

(74) Common Representative: BAYER AKTIENGESELLSCHAFT; 51368 Leverkusen (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 2-NAPHTHAMIDE DERIVATIVES

(57) **Abstract:** The present invention relates to 2-naphthamides, which are useful as an active ingredient of pharmaceutical preparations. The 2-naphthamides of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benign prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiopathic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since the disease is also alleviated by treatment with an IP receptor antagonist.